Advertisement

Topics

Correction to: Andexanet Alfa: First Global Approval.

08:00 EDT 21st July 2018 | BioPortfolio

Summary of "Correction to: Andexanet Alfa: First Global Approval."

The article Andexanet Alfa: First Global Approval, written by Young-A Heo, was originally published Online First without open access.

Affiliation

Journal Details

This article was published in the following journal.

Name: Drugs
ISSN: 1179-1950
Pages:

Links

DeepDyve research library

PubMed Articles [6126 Associated PubMed Articles listed on BioPortfolio]

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.

A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet alfa (Andexxa®).

The use of direct oral anticoagulants over traditional warfarin has increased in the United States over the past 10 years due to advantages such as ease of use, predictable pharmacokinetic response, a...

Correction to: Ivosidenib: First Global Approval.

IThe article Ivosidenib: First Global Approval, written by Sohita Dhillon, was originally published Online First without open access.

Correction to: Moxetumomab Pasudotox: First Global Approval.

The article Moxetumomab Pasudotox: First Global Approval, written by Sohita Dhillon, was originally published Online First without open access.

Pyrotinib: First Global Approval.

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the d...

Clinical Trials [2831 Associated Clinical Trials listed on BioPortfolio]

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

This is a randomized, double-blind, study in healthy volunteers dosed to steady state with fXa inhibitors, designed to (1) demonstrate PK/PD comparability between andexanet manufactured by...

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

This is a randomized, double-blind, single center study in healthy volunteers dosed to steady state with betrixaban, designed to (1) Determine an andexanet dosing regimen required to rever...

Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct or...

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

"This is a single-center, randomized, double-blind, and placebo-controlled trial designed to: 1) demonstrate the degree to which administered andexanet doses can reverse Factor Ten A (FXa)...

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

The purpose of this study in early hemodialysis patients (on dialysis 3 to 18 months) is to assess the effect of correction versus partial correction of anemia using epoetin alfa on heart ...

Medical and Biotech [MESH] Definitions

A recombinant alfa interferon consisting of 165 amino acids with arginine at positions 23 and 34. It is used extensively as an antiviral and antineoplastic agent.

A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent.

A recombinant alfa interferon consisting of 165 amino acid residues with arginine in position 23 and histidine in position 34. It is used extensively as an antiviral and antineoplastic agent.

Increase in the temperature of the atmosphere near the Earth's surface and in the troposphere, which can contribute to changes in global climate patterns.

Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article